X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The combined oncology company will advance Flamingo's lead programs, Danvatirsen (antisence oligonucleotide) in a Phase II trial PEMDA-HN in Head & Neck cancer (danvatirsen in combination with pembrolizumab) and other indications; and FTX-001 targeting MALAT-1 in cancer.
Lead Product(s): Antisence Oligonucleotide,Pembrolizumab
Therapeutic Area: Oncology Product Name: Danvatirsen
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: Flamingo Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger March 02, 2023
Details:
Fast Track Designation recieved for DYN101,an investigational antisense product candidate designed to reduce the expression of dynamin 2 protein for the treatment of Myotubular and Centronuclear Myopathies.
Lead Product(s): DYN101
Therapeutic Area: Genetic Disease Product Name: DYN101
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2022
Details:
Under the terms of the agreement, Nippon Shinyaku has secured opt-in rights to exclusively pursue the development and commercialization of DYN101 in Japan depending on analysis of interim data from the Phase 1/2 study, UNITE-CNM.
Lead Product(s): DYN101
Therapeutic Area: Genetic Disease Product Name: DYN101
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Nippon Shinyaku
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 10, 2021
Details:
U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation for DYN101, an investigational antisense medicine designed to modulate the expression of dynamin 2 (DNM2), for the treatment of Myotubular and Centronuclear Myopathies (CNM).
Lead Product(s): Dynamin 101
Therapeutic Area: Musculoskeletal Product Name: DYN101
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 30, 2020
Details:
Funding supports ongoing Phase 1 / 2 'Unite-CNM' study of DYN101 in Patients with Myotubular and Centronuclear Myopathies.
Lead Product(s): DYN101
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Perceptive Advisors
Deal Size: $54.6 million Upfront Cash: Undisclosed
Deal Type: Series C Financing April 02, 2020
Details:
This clinical trial, based on Ionis' technology platform, is the first investigational study testing an antisense medicine to treat Centronuclear Myopathies.
Lead Product(s): DYN101
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
